Results 131 to 140 of about 5,281 (177)
Some of the next articles are maybe not open access.
Update on emerging urate-lowering therapies
Current Opinion in Rheumatology, 2009To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development.Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple ...
Saima, Chohan, Michael A, Becker
openaire +2 more sources
Cardiovascular Safety of Urate Lowering Therapies
Current Rheumatology Reports, 2019The effect of urate lowering treatment (ULT) on cardiovascular (CV) risk and mortality in gout has been a topic of interest. This review discusses the CV effect of ULT and comparative CV safety among ULT agents.The mechanism linking gout with CV risk is not fully understood but seems multifactorial involving hyperuricemia, xanthine oxidase (XO ...
Eun Ha, Kang, Seoyoung C, Kim
openaire +2 more sources
Potential Dangers of Serum Urate-Lowering Therapy
The American Journal of Medicine, 2019In observational studies, high serum urate levels are associated with adverse outcomes, including mortality. However, the hypothesis that urate-lowering may improve nongout outcomes has not been confirmed by placebo-controlled clinical trials. On the contrary, 7 recent placebo-controlled trials of urate-lowering drugs with different mechanisms of ...
Maria Vanessa Perez-Gomez +5 more
openaire +2 more sources
Expert opinion on emerging urate-lowering therapies
Expert Opinion on Emerging Drugs, 2018There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate ...
Lisa K, Stamp +2 more
openaire +2 more sources
Arthritis & Rheumatology, 2022
ObjectiveTo determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.MethodsWe undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of
Nicola Dalbeth +12 more
openaire +2 more sources
ObjectiveTo determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.MethodsWe undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of
Nicola Dalbeth +12 more
openaire +2 more sources
Urate‐Lowering Therapy for Gout: Focus on Febuxostat
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010Gout is a common, painful, and often debilitating rheumatologic disorder that remains one of the few arthritic conditions that can be diagnosed with certainty and cured with appropriate therapy. Allopurinol is the most frequently prescribed agent for gout in the United States.
Bryan L, Love +3 more
openaire +2 more sources
Urate-Lowering Therapy and Chronic Kidney Disease Progression
New England Journal of Medicine, 2020The prevalence and severity of chronic kidney disease (CKD) has been increasing for decades. Because of its tremendous financial and health burden, both to persons and to health systems, mitigation...
openaire +2 more sources
2016
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
openaire +1 more source
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
openaire +1 more source